Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIZhen-kai ,  DONGMao-sheng

Department of General Surgery, The Second Artillery General Hospital PLA, Beijing 100088, China;

Corresponding author：

DONGMao-sheng, Email: 13051186112@163.com

Keywords：

Advanced gastric cancer; Preoperative regional-arterial chemotherapy

DOI：

10.7507/1007-9424.20150369

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of preoperative regional-arterial chemotherapy in advanced gastric cancer. Method The literatures about the research progress of preoperative regional-arterial chemotherapy in the advanced gastric cancer were reviewed. Results The preoperative regional-arterial chemotherapy in the advanced gastric cancer could decrease the tumour stage, improve the R0 resection rate and the long-term survival rate, effectively improve the drug concentrations of tumor and portal vein, and not only kill or damage cancer cells directly, but also prevent the metastasis of liver and lymph nodes effectively, and reduce the side effects, cause the nuclear pyknosis and fracture of cancer cells in a short time. The course of preoperative regional-arterial chemotherapy in the advanced gastric cancer generally was 4-9 weeks, and then whether the surgery treatment was decided to undergo according to the results of the curative effect evaluation. Conclusions The preoperative regional-arterial chemotherapy in the advanced gastric cancer has more advantages than intravenous chemotherapy, further research of multicenter and large clinical trials, would inaugurate a wider application prospects.

Citation： LIZhen-kai, DONGMao-sheng. Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(11): 1410-1415. doi: 10.7507/1007-9424.20150369 Copy

1.	季加孚.胃肠道肿瘤的新辅助治疗.中国实用外科杂志, 2005, 5(25):261-263.
2.	左朝晖, 欧阳永忠, 汤明, 等.胃癌的综合治疗研究的进展.中华普外科手术学杂志:电子版, 2012, 6(3):319-324.
3.	Kong SH, Yang HK. Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer, 2013, 13(1):3-18.
4.	Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1288-1291.
5.	Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg, 2006, 95(4):270-273.
6.	王义平, 王金林, 何世保, 等.介入动脉灌注化疗在晚期胃癌中的疗效观察.中外医疗, 2013, 33(33):22-23.
7.	李东, 吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究.中国癌症杂志, 2010, 20(4):290-294.
8.	Ensminger WD. Intrahepatic arterial infusion of chemotherapy:pharmacologic principles. Semin Oncol, 2002, 29(2):119-125.
9.	Pohlen U, Rieger H, Kunick-Pohlen S, et al. PhaseⅡstudy of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res, 2007, 27(1B):667-674.
10.	詹晓星, 颜小琼.介入放射学中的药代动力学研究.国外医学:临床放射学分册, 1989, 126(6):327-329.
11.	邹寿椿, 裘华森, 陈方宏, 等.胃癌血供与供血动脉插管化疗的临床观察.中国实用外科杂志, 1996, 16(11):20-21.
12.	Link H, Aigner KR, Kuehn W, et al. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res, 1986, 46(9):4837-4840.
13.	Araki K, Yamamoto H, Kobayashi M, et al. Experimental and clinical study on intraoperative local infusion chemotherapy (ILIC) for advanced gastric carcinoma. Gan To Kagaku Ryoho, 1995, 22(11):1531-1534.
14.	Maurer CA, Borner M, Buchler MW, et al. Regional chemotherapy of gastrointestinal cancer. Dig Surg, 1997, 14(1):9-22.
15.	李澍.进展期胃癌术中实施区域性缓释化疗安全性和远期疗效观察.临床和实验医学杂志, 2014, 13(22):1863-1865.
16.	Shchepotin IB, Chorny V, Hanfelt J, et al. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg, 2000, 3(4):426-431.
17.	朱志东, 蒲永东.氟尿嘧啶经胃左动脉和外周静脉化疗的药代动力学比较.中国胃肠外科杂志, 2000, 3(1):28-30.
18.	吴鹏, 朱正纲, 叶正宝, 等. 5-氟尿嘧啶-2'-脱氧核苷经胃左动脉介入灌注后的药代动力学实验研究.外科理论与实践, 2004, 9(2):135-139.
19.	徐光炜.胃癌手术辅助化学疗法.北京:人民卫生出版社, 1987:251-259.
20.	刘福坤, 陈忠豪, 李国立, 等.胃癌术前介入治疗后血管变化与癌组织坏死的关系.世界华人消化杂志, 1998, 6(8):686-688.
21.	孙碎康, 蒲青凡, 严律南, 等.胃癌病人术前选择性动脉栓塞化疗对肿瘤血管的影响.中国普通外科杂志, 2002, 11(4):202-204.
22.	杨秀超, 崔振玉, 李正华.经动脉插管灌注抗癌药提高胃癌手术疗效.中华外科杂志, 1994, 32(7):403-404.
23.	徐工学, 李志霞, 陈佛来, 等.术前区域性动脉灌注化疗对大肠癌细胞凋亡相关基因的影响.中华外科杂志, 2001, 39(6):436-439.
24.	蒲青凡, 孙碎康, 刘占培, 等.术前胃动脉化疗栓塞对胃癌淋巴结转移灶癌细胞凋亡的影响.中国普外基础与临床杂志, 2006, 13(4):427-430.
25.	徐圣德, 高斌, 文刚, 等.术前动脉化疗对进展期胃癌细胞凋亡和增殖的影响.介入放射学杂志, 2007, 16(5):353-356.
26.	彭飞, 陈冬峨, 陈华.胃癌p53癌基因表达的Meta分析.数理医药学杂志, 2004, 17(6):540-542.
27.	Fujimoto S, Watanabe Y, Enomoto K, et al. Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer, 1969, 24(3):433-441.
28.	Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
29.	刘锐锋, 王小琦, 王小虎, 等.术前动脉灌注化疗治疗局部晚期胃癌的系统评价.肿瘤防治研究, 2012, 39(9):1098-1106.
30.	吴震峰, 朱文强, 曹勤洪, 等.区域动脉灌注化疗在进展期胃癌短程新辅助化疗中的应用.中华胃肠外科杂志, 2014, 17(11):1092-1095.
31.	Zhang CW, Zou SC, Shi D, et al. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol, 2004, 10(20):3070-3072.
32.	Flörcken A, Schaefer C, Bichev D, et al. Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer:an analysis in Western patients. Tumori, 2011, 97(1):19-24.
33.	Wang YY, Zhang W, Qian S, et al. The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. J Int Med Res, 2012, 40(3):1141-1148.
34.	高登鹏, 张霄成, 石秀玲, 等.胃癌术中术后局部化疗对癌细胞及患者预后的影响.现代中西医结合杂志, 2005, 14(19):2535-2537.
35.	李东, 吴萍山, 赵宏.进展期胃癌术前介入化疗的疗效观察.肿瘤学杂志, 2003, 9(4):201-203.
36.	李国立, 刘福坤, 陈忠豪, 等.胃癌术前选择性动脉化疗对组织和细胞结构的影响.中华外科杂志, 1997, 35(5):4-6, 66.
37.	肖乾虎, 程中, 卢武胜, 等.胃癌术前行选择性动脉插管灌注抗癌药物治疗与一般化疗的疗效比较.临床外科杂志, 1996, 4(4):190-192.
38.	金雪熙, 杨大明, 徐幼龙, 等.胃癌术前选择性动脉灌注化疗.介入放射学杂志, 2001, 10(6):344-345.
39.	卞育海, 陈治平, 庄捷, 等.术前经动脉化疗在胃癌综合治疗中的应用.消化外科, 2002, 1(5):337-339.
40.	Kennedy BJ. The unified international gastric cancer staging classification system. Scand J Gastroenterol, 1987, 22(Suppl 133):11.
41.	Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol, 2010, 25(3):512-518.
42.	Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer:comparison with contrastenhanced CT. Eur J Radiol, 2011, 79(2):183-188.
43.	Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol, 2014, 20(7):1650-1656.
44.	葛梅英, 尹化斌, 葛菁芳, 等.小网膜受胃癌侵犯的CT表现及其对病变扩散蔓延的影响研究.实用放射学杂志, 2014(5):786-789, 807.
45.	Ittrich H, Peldschus K, Raabe N, et al. Superparamagnetic iron oxide nanoparticles in biomedicine:applications and developments in diagnostics and therapy. Rofo, 2013, 185(12):1149-1166.
46.	涂敏, 朱振舒, 时林森, 等.胃癌转移淋巴结评估手段的研究现状及远景.中华胃肠外科杂志, 2012, 15(2):197-200.
47.	Mortensen MB, Fristrup C, Ainsworth A, et al. Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc, 2011, 25(3):804-812.
48.	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
49.	Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer, 1998, 1(1):10-24.
50.	Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 2003, 98(7):1521-1530.
51.	Kobayashi M, Yamamoto H, Sugimoto T, et al. Intraoperative local infusion chemotherapy (ILIC) for gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1281-1283.
52.	Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 1997, 15(1):261-267.
53.	Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phaseⅢtrial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 2000, 18(14):2648-2657.
54.	Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002, 20(8):1996-2004.
55.	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1):11-20.
56.	Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. J Clin Oncol, 2006, 24(31):4991-4997.
57.	依荷芭丽.迟, 任建鸿, 杨林, 等.改良后DCF方案治疗进展期胃癌Ⅱ期临床研究.中国北京.第三届中国肿瘤内科大会教育集论文集, 2009.
58.	周娜, 应红艳, 宁晓红, 等.多西他赛联合顺铂及氟尿嘧啶(DCF)改良方案治疗晚期胃癌疗效观察.基础医学与临床, 2012, 32(12):1456-1460.
59.	Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
60.	Kinoshita T, Gotohda N, Kato Y, et al. Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach:a retrospective comparison with open surgery. Surg Endosc, 2013, 27:146-153.
61.	Zhao JG, Qiu F, Xiong JP, et al. A phaseⅡstudy of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs, 2009, 20(4):281-286.
62.	Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 2008, 61(4):623-629.
63.	Van Ness PH, Peduzzi PN, Quagliarello VJ. Efficacy and effectiveness as aspects of cluster randomized trials with nursing home residents:methodological insights from a pneumonia prevention trial. Contemp Clin Trials, 2012, 33:1124-1131.
64.	Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phaseⅢnoninferiority trial. Ann Oncol, 2009, 20(4):666-673.
65.	Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) +5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol (Meeting Abstracts), 2005, 23(16_suppl):4003.
66.	Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phaseⅢcomparison of cisplatin/S-1(CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS):Secondary and subset analyses. J Clin Oncol, 2009, 27(15_suppl):4511.
67.	Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial:A phaseⅢstudy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer (GC). J Clin Oncol, 2009, 27(15_suppl):4507.
68.	Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phaseⅢtrial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium, 2010:59-66.
69.	Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 2010, 28(18_suppl):LBA4007.
70.	葛来增, 吴仕光, 龚立鹏, 等.胃动脉介入化疗栓塞联合根治术治疗进展期胃癌.肿瘤防治研究, 2007, 34(4):300-302.
71.	李东, 吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究.中国癌症杂志, 2010, 20(4):290-294.
72.	余传定, 王新保.胃癌新辅助化疗研究进展.中国肿瘤, 2004, 13(11):41-44.
73.	沈琳.进展期胃癌新辅助化疗研究与实践.消化肿瘤杂志:电子版, 2009, 1(1):15-17.
74.	Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer:is there enough evidence to call second-line therapy standard? World J Gastroenterol, 2012, 18(44):6376-6378.
75.	Shrikhande SV, Barreto SG, Talole SD, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol, 2013, 11:31.

1. 季加孚.胃肠道肿瘤的新辅助治疗.中国实用外科杂志, 2005, 5(25):261-263.
2. 左朝晖, 欧阳永忠, 汤明, 等.胃癌的综合治疗研究的进展.中华普外科手术学杂志:电子版, 2012, 6(3):319-324.
3. Kong SH, Yang HK. Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer, 2013, 13(1):3-18.
4. Kosaka T, Ueshige N, Sugaya J, et al. Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1288-1291.
5. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer. Scand J Surg, 2006, 95(4):270-273.
6. 王义平, 王金林, 何世保, 等.介入动脉灌注化疗在晚期胃癌中的疗效观察.中外医疗, 2013, 33(33):22-23.
7. 李东, 吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究.中国癌症杂志, 2010, 20(4):290-294.
8. Ensminger WD. Intrahepatic arterial infusion of chemotherapy:pharmacologic principles. Semin Oncol, 2002, 29(2):119-125.
9. Pohlen U, Rieger H, Kunick-Pohlen S, et al. PhaseⅡstudy of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res, 2007, 27(1B):667-674.
10. 詹晓星, 颜小琼.介入放射学中的药代动力学研究.国外医学:临床放射学分册, 1989, 126(6):327-329.
11. 邹寿椿, 裘华森, 陈方宏, 等.胃癌血供与供血动脉插管化疗的临床观察.中国实用外科杂志, 1996, 16(11):20-21.
12. Link H, Aigner KR, Kuehn W, et al. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res, 1986, 46(9):4837-4840.
13. Araki K, Yamamoto H, Kobayashi M, et al. Experimental and clinical study on intraoperative local infusion chemotherapy (ILIC) for advanced gastric carcinoma. Gan To Kagaku Ryoho, 1995, 22(11):1531-1534.
14. Maurer CA, Borner M, Buchler MW, et al. Regional chemotherapy of gastrointestinal cancer. Dig Surg, 1997, 14(1):9-22.
15. 李澍.进展期胃癌术中实施区域性缓释化疗安全性和远期疗效观察.临床和实验医学杂志, 2014, 13(22):1863-1865.
16. Shchepotin IB, Chorny V, Hanfelt J, et al. Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer. J Gastrointest Surg, 2000, 3(4):426-431.
17. 朱志东, 蒲永东.氟尿嘧啶经胃左动脉和外周静脉化疗的药代动力学比较.中国胃肠外科杂志, 2000, 3(1):28-30.
18. 吴鹏, 朱正纲, 叶正宝, 等. 5-氟尿嘧啶-2'-脱氧核苷经胃左动脉介入灌注后的药代动力学实验研究.外科理论与实践, 2004, 9(2):135-139.
19. 徐光炜.胃癌手术辅助化学疗法.北京:人民卫生出版社, 1987:251-259.
20. 刘福坤, 陈忠豪, 李国立, 等.胃癌术前介入治疗后血管变化与癌组织坏死的关系.世界华人消化杂志, 1998, 6(8):686-688.
21. 孙碎康, 蒲青凡, 严律南, 等.胃癌病人术前选择性动脉栓塞化疗对肿瘤血管的影响.中国普通外科杂志, 2002, 11(4):202-204.
22. 杨秀超, 崔振玉, 李正华.经动脉插管灌注抗癌药提高胃癌手术疗效.中华外科杂志, 1994, 32(7):403-404.
23. 徐工学, 李志霞, 陈佛来, 等.术前区域性动脉灌注化疗对大肠癌细胞凋亡相关基因的影响.中华外科杂志, 2001, 39(6):436-439.
24. 蒲青凡, 孙碎康, 刘占培, 等.术前胃动脉化疗栓塞对胃癌淋巴结转移灶癌细胞凋亡的影响.中国普外基础与临床杂志, 2006, 13(4):427-430.
25. 徐圣德, 高斌, 文刚, 等.术前动脉化疗对进展期胃癌细胞凋亡和增殖的影响.介入放射学杂志, 2007, 16(5):353-356.
26. 彭飞, 陈冬峨, 陈华.胃癌p53癌基因表达的Meta分析.数理医药学杂志, 2004, 17(6):540-542.
27. Fujimoto S, Watanabe Y, Enomoto K, et al. Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer, 1969, 24(3):433-441.
28. Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
29. 刘锐锋, 王小琦, 王小虎, 等.术前动脉灌注化疗治疗局部晚期胃癌的系统评价.肿瘤防治研究, 2012, 39(9):1098-1106.
30. 吴震峰, 朱文强, 曹勤洪, 等.区域动脉灌注化疗在进展期胃癌短程新辅助化疗中的应用.中华胃肠外科杂志, 2014, 17(11):1092-1095.
31. Zhang CW, Zou SC, Shi D, et al. Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer. World J Gastroenterol, 2004, 10(20):3070-3072.
32. Flörcken A, Schaefer C, Bichev D, et al. Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer:an analysis in Western patients. Tumori, 2011, 97(1):19-24.
33. Wang YY, Zhang W, Qian S, et al. The effect of locoregional transarterial infusion chemotherapy on liver metastasis after gastric cancer resection. J Int Med Res, 2012, 40(3):1141-1148.
34. 高登鹏, 张霄成, 石秀玲, 等.胃癌术中术后局部化疗对癌细胞及患者预后的影响.现代中西医结合杂志, 2005, 14(19):2535-2537.
35. 李东, 吴萍山, 赵宏.进展期胃癌术前介入化疗的疗效观察.肿瘤学杂志, 2003, 9(4):201-203.
36. 李国立, 刘福坤, 陈忠豪, 等.胃癌术前选择性动脉化疗对组织和细胞结构的影响.中华外科杂志, 1997, 35(5):4-6, 66.
37. 肖乾虎, 程中, 卢武胜, 等.胃癌术前行选择性动脉插管灌注抗癌药物治疗与一般化疗的疗效比较.临床外科杂志, 1996, 4(4):190-192.
38. 金雪熙, 杨大明, 徐幼龙, 等.胃癌术前选择性动脉灌注化疗.介入放射学杂志, 2001, 10(6):344-345.
39. 卞育海, 陈治平, 庄捷, 等.术前经动脉化疗在胃癌综合治疗中的应用.消化外科, 2002, 1(5):337-339.
40. Kennedy BJ. The unified international gastric cancer staging classification system. Scand J Gastroenterol, 1987, 22(Suppl 133):11.
41. Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol, 2010, 25(3):512-518.
42. Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer:comparison with contrastenhanced CT. Eur J Radiol, 2011, 79(2):183-188.
43. Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol, 2014, 20(7):1650-1656.
44. 葛梅英, 尹化斌, 葛菁芳, 等.小网膜受胃癌侵犯的CT表现及其对病变扩散蔓延的影响研究.实用放射学杂志, 2014(5):786-789, 807.
45. Ittrich H, Peldschus K, Raabe N, et al. Superparamagnetic iron oxide nanoparticles in biomedicine:applications and developments in diagnostics and therapy. Rofo, 2013, 185(12):1149-1166.
46. 涂敏, 朱振舒, 时林森, 等.胃癌转移淋巴结评估手段的研究现状及远景.中华胃肠外科杂志, 2012, 15(2):197-200.
47. Mortensen MB, Fristrup C, Ainsworth A, et al. Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc, 2011, 25(3):804-812.
48. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
49. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 2nd English Edition. Gastric Cancer, 1998, 1(1):10-24.
50. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer, 2003, 98(7):1521-1530.
51. Kobayashi M, Yamamoto H, Sugimoto T, et al. Intraoperative local infusion chemotherapy (ILIC) for gastric cancer. Gan To Kagaku Ryoho, 1998, 25(9):1281-1283.
52. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 1997, 15(1):261-267.
53. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phaseⅢtrial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer:A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 2000, 18(14):2648-2657.
54. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol, 2002, 20(8):1996-2004.
55. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1):11-20.
56. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group. J Clin Oncol, 2006, 24(31):4991-4997.
57. 依荷芭丽.迟, 任建鸿, 杨林, 等.改良后DCF方案治疗进展期胃癌Ⅱ期临床研究.中国北京.第三届中国肿瘤内科大会教育集论文集, 2009.
58. 周娜, 应红艳, 宁晓红, 等.多西他赛联合顺铂及氟尿嘧啶(DCF)改良方案治疗晚期胃癌疗效观察.基础医学与临床, 2012, 32(12):1456-1460.
59. Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusionchemotherapy:A case report. Oncol Lett, 2014, 7(2):449-451.
60. Kinoshita T, Gotohda N, Kato Y, et al. Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach:a retrospective comparison with open surgery. Surg Endosc, 2013, 27:146-153.
61. Zhao JG, Qiu F, Xiong JP, et al. A phaseⅡstudy of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs, 2009, 20(4):281-286.
62. Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 2008, 61(4):623-629.
63. Van Ness PH, Peduzzi PN, Quagliarello VJ. Efficacy and effectiveness as aspects of cluster randomized trials with nursing home residents:methodological insights from a pneumonia prevention trial. Contemp Clin Trials, 2012, 33:1124-1131.
64. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phaseⅢnoninferiority trial. Ann Oncol, 2009, 20(4):666-673.
65. Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11) +5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients. J Clin Oncol (Meeting Abstracts), 2005, 23(16_suppl):4003.
66. Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phaseⅢcomparison of cisplatin/S-1(CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS):Secondary and subset analyses. J Clin Oncol, 2009, 27(15_suppl):4511.
67. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial:A phaseⅢstudy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer (GC). J Clin Oncol, 2009, 27(15_suppl):4507.
68. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phaseⅢtrial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. 2010 Gastrointestinal Cancers Symposium, 2010:59-66.
69. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST:A randomized, double-blind, placebo-controlled, phaseⅢstudy of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol, 2010, 28(18_suppl):LBA4007.
70. 葛来增, 吴仕光, 龚立鹏, 等.胃动脉介入化疗栓塞联合根治术治疗进展期胃癌.肿瘤防治研究, 2007, 34(4):300-302.
71. 李东, 吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究.中国癌症杂志, 2010, 20(4):290-294.
72. 余传定, 王新保.胃癌新辅助化疗研究进展.中国肿瘤, 2004, 13(11):41-44.
73. 沈琳.进展期胃癌新辅助化疗研究与实践.消化肿瘤杂志:电子版, 2009, 1(1):15-17.
74. Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer:is there enough evidence to call second-line therapy standard? World J Gastroenterol, 2012, 18(44):6376-6378.
75. Shrikhande SV, Barreto SG, Talole SD, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol, 2013, 11:31.

Previous Article
Research Progress of Lymph Node Dissection in Treatment of cN0 Papillary Thyroid Microcarcinoma
Next Article
高分辨肛管直肠测压对肛管括约肌功能障碍的诊断(1例报道)

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Preoperative Regional-arterial Chemotherapy in Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content